You just read:

Results From Phase 3 FRAME Study Of Romosozumab Showed Significant Reductions In Both New Vertebral And Clinical Fractures In Postmenopausal Women With Osteoporosis

News provided by

Amgen

Sep 18, 2016, 11:00 ET